FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS Share Price

Certificat

DE000MG23886

Real-time Bid/Ask 05:46:45 23/05/2024 pm IST
7.9 EUR / 8.03 EUR +1.34% Intraday chart for FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS
Current month-19.05%
1 month-18.55%
Date Price Change
23/24/23 7.89 +0.38%
22/24/22 7.86 +0.51%
21/24/21 7.82 -4.40%
20/24/20 8.18 +9.80%
17/24/17 7.45 -3.37%

Delayed Quote Börse Stuttgart

Last update May 23, 2024 at 03:57 pm IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying IONIS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MG2388
ISINDE000MG23886
Date issued 10/04/2024
Strike 18.69 $
Maturity Unlimited
Parity 2.25 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10.75
Lowest since issue 7.37
Spread 0.13
Spread %1.62%

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Sector
-
More about the company

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Ionis Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
38 USD
Average target price
57.95 USD
Spread / Average Target
+52.50%
Consensus